Is male or female and ≥55 and ≤95 years of age living in the community or in an institutionalized setting
Meets clinical criteria for possible or probable AD based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria
Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the International Psychogeriatrics Association (IPA)
Has either blood-based biomarker or documented evidence (e.g. positron emission tomography, cerebrospinal fluid biomarker) indicating amyloid plaque deposition and neuropathologic change consistent with AD
Has a prior magnetic resonance imaging or computed tomography scan of the brain that is consistent with the diagnosis of AD
Meets revised criteria for psychosis in major or mild neurocognitive disorder as per International Psychogeriatrics Association
MMSE score ≥6 and ≤24
Psychotic symptoms for at least 2 months
Lives in a stable place of residence and there are no plans to change living arrangements
Has a designated study partner/caregiver
Able to complete all study visits with a study partner/caregiver
Must be on a stable dose of cholinesterase inhibitor or memantine, if applicable
You may not be if
Requires treatment with a medication prohibited by the protocol
Is in hospice and receiving end-of-life palliative care, or has become bedridden
Requires skilled nursing care
Psychotic symptoms that are primarily attributable to delirium, substance abuse, or a medical or psychiatric condition other than dementia
Known history of cerebral amyloid angiopathy, epilepsy, central nervous system neoplasm, or unexplained syncope
